Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: A scoping review

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity : A scoping review. / Baden, Christoffer S.; Andersen, Jon T.; Christensen, Mikkel B.; Gade, Christina.

I: Adverse Drug Reaction Bulletin, Bind 339, Nr. 1, 2023, s. 1315-1318.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Baden, CS, Andersen, JT, Christensen, MB & Gade, C 2023, 'Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: A scoping review', Adverse Drug Reaction Bulletin, bind 339, nr. 1, s. 1315-1318. https://doi.org/10.1097/FAD.0000000000000067

APA

Baden, C. S., Andersen, J. T., Christensen, M. B., & Gade, C. (2023). Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: A scoping review. Adverse Drug Reaction Bulletin, 339(1), 1315-1318. https://doi.org/10.1097/FAD.0000000000000067

Vancouver

Baden CS, Andersen JT, Christensen MB, Gade C. Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: A scoping review. Adverse Drug Reaction Bulletin. 2023;339(1):1315-1318. https://doi.org/10.1097/FAD.0000000000000067

Author

Baden, Christoffer S. ; Andersen, Jon T. ; Christensen, Mikkel B. ; Gade, Christina. / Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity : A scoping review. I: Adverse Drug Reaction Bulletin. 2023 ; Bind 339, Nr. 1. s. 1315-1318.

Bibtex

@article{fe9175b575b74db38ed8d3309cf985e5,
title = "Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: A scoping review",
abstract = "As obesity continues to be a global health challenge presenting various negative impacts on health outcomes and healthcare costs, there is a growing need for pharmacological interventions to address the issue. Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes, but there is a lack of studies comparing adverse events across different populations. This review intends to indirectly compare the adverse events of available glucagon-like peptide-1 receptor agonist pharmaceuticals for treating overweight or obesity in adults, adolescents, and children.",
author = "Baden, {Christoffer S.} and Andersen, {Jon T.} and Christensen, {Mikkel B.} and Christina Gade",
note = "Publisher Copyright: {\textcopyright} 2023 Lippincott Williams and Wilkins. All rights reserved.",
year = "2023",
doi = "10.1097/FAD.0000000000000067",
language = "English",
volume = "339",
pages = "1315--1318",
journal = "Adverse Drug Reaction Bulletin",
issn = "0044-6394",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

RIS

TY - JOUR

T1 - Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity

T2 - A scoping review

AU - Baden, Christoffer S.

AU - Andersen, Jon T.

AU - Christensen, Mikkel B.

AU - Gade, Christina

N1 - Publisher Copyright: © 2023 Lippincott Williams and Wilkins. All rights reserved.

PY - 2023

Y1 - 2023

N2 - As obesity continues to be a global health challenge presenting various negative impacts on health outcomes and healthcare costs, there is a growing need for pharmacological interventions to address the issue. Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes, but there is a lack of studies comparing adverse events across different populations. This review intends to indirectly compare the adverse events of available glucagon-like peptide-1 receptor agonist pharmaceuticals for treating overweight or obesity in adults, adolescents, and children.

AB - As obesity continues to be a global health challenge presenting various negative impacts on health outcomes and healthcare costs, there is a growing need for pharmacological interventions to address the issue. Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes, but there is a lack of studies comparing adverse events across different populations. This review intends to indirectly compare the adverse events of available glucagon-like peptide-1 receptor agonist pharmaceuticals for treating overweight or obesity in adults, adolescents, and children.

U2 - 10.1097/FAD.0000000000000067

DO - 10.1097/FAD.0000000000000067

M3 - Review

AN - SCOPUS:85151815843

VL - 339

SP - 1315

EP - 1318

JO - Adverse Drug Reaction Bulletin

JF - Adverse Drug Reaction Bulletin

SN - 0044-6394

IS - 1

ER -

ID: 344447603